Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
M&A
CRO
Crown stays put as $204M Adicon deal falls through
Crown originally planned to transfer all its shares to a subsidiary of Adicon Holdings before the parties mutually agreed to end the pact.
Marissa Russo
Nov 19, 2026 4:55pm
Lilly gets fresh myelofibrosis option via $1.5B Calytrix buyout
Nov 16, 2026 9:49am
Fierce Pharma
AZ’s reported $10B offer for Rhythm fuels talks of a bidding war
Nov 5, 2026 9:36am
Treasury COINS rules add biotech, spares China licensing deals
Oct 22, 2026 11:36pm
Lexeo acquires Mantle for $8M, adding Friedreich ataxia assets
Sep 22, 2026 9:58am
Newly formed Jaguar acquires Afib device assets from J&J
Sep 15, 2026 11:11am